ARS Pharmaceuticals, Inc. (SPRY)
(Real Time Quote from BATS)
$13.54 USD
0.00 (0.00%)
Updated Aug 16, 2024 12:50 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for ARS Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 1 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 1 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 68 | 37 | 90 | 33 | 24 |
Income After Depreciation & Amortization | -68 | -36 | -90 | -33 | -24 |
Non-Operating Income | 13 | 1 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -54 | -35 | -89 | -33 | -24 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -54 | -35 | -89 | -33 | -24 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -54 | -35 | -89 | -33 | -24 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -74 | -35 | -89 | -32 | -23 |
Depreciation & Amortization (Cash Flow) | -7 | 0 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -68 | -36 | -90 | -33 | -24 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 95.22 | 39.96 | 34.93 | 2.91 | NA |
Diluted EPS Before Non-Recurring Items | -0.57 | -0.87 | -2.56 | -11.33 | NA |
Diluted Net EPS (GAAP) | -0.57 | -0.87 | -2.56 | -11.33 | NA |
Fiscal Year end for ARS Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.50 | 0.00 | 0.00 | 0.00 | 0.01 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.50 | 0.00 | 0.00 | 0.00 | 0.01 |
SG&A, R&D, and Dept/Amort Expenses | 15.84 | 13.19 | 10.22 | 17.98 | 20.62 |
Income After SG&A, R&D, and Dept/Amort Expenses | -15.34 | -13.19 | -10.22 | -17.98 | -20.61 |
Non-Operating Income | 2.82 | 2.90 | 3.06 | 3.11 | 3.23 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -12.52 | -10.29 | -7.17 | -14.87 | -17.37 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -12.52 | -10.29 | -7.17 | -14.87 | -17.37 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -12.52 | -10.29 | -7.17 | -14.87 | -17.37 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 96.83 | 96.49 | 95.22 | 95.58 | 94.91 |
Diluted EPS Before Non-Recurring Items | -0.13 | -0.11 | -0.07 | -0.16 | -0.18 |
Diluted Net EPS (GAAP) | -0.13 | -0.11 | -0.07 | -0.16 | -0.18 |